We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

109 hedge funds and large institutions have $400M invested in CytomX Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 29 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 29

0% more capital invested

Capital invested by funds: $399M → $400M (+$262K)

9% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 22

3.52% less ownership

Funds ownership: 82.19% → 78.67% (-3.5%)

4% less funds holding

Funds holding: 113 → 109 (-4)

Holders
109
Holders Change
-4
Holders Change %
-3.54%
% of All Funds
2.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
43
Reduced
29
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
+$7.8M
2
BI
BVF Inc
California
+$7.08M
3
Millennium Management
Millennium Management
New York
+$4.04M
4
Victory Capital Management
Victory Capital Management
Texas
+$3.46M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.72M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$10.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.55M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
-$6.57M
4
State Street
State Street
Massachusetts
-$3.78M
5
First Manhattan
First Manhattan
New York
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$2.64M +$1.54M +146,647 +165%
BBA
27
Baker Bros. Advisors
New York
$2.18M – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.04M -$49.7K -4,744 -3%
Allianz Asset Management
29
Allianz Asset Management
Germany
$2.03M -$1.6M -152,747 -46%
AllianceBernstein
30
AllianceBernstein
Tennessee
$1.89M – – –
CPC
31
Congress Park Capital
New York
$1.72M -$450K -42,895 -20%
Acadian Asset Management
32
Acadian Asset Management
Massachusetts
$1.68M +$310K +29,568 +25%
PAG
33
Private Advisor Group
New Jersey
$1.65M -$167K -15,907 -10%
GIM
34
Granahan Investment Management
Massachusetts
$1.65M -$96.1K -9,168 -6%
Two Sigma Investments
35
Two Sigma Investments
New York
$1.51M +$419K +39,922 +42%
USAA
36
United Services Automobile Association
Texas
$1.5M -$19.6K -1,870 -1%
MCM
37
Moore Capital Management
New York
$1.4M – – –
Assenagon Asset Management
38
Assenagon Asset Management
Luxembourg
$1.4M +$1.3M +124,400 New
JP Morgan Chase
39
JP Morgan Chase
New York
$1.35M -$75.1K -7,166 -5%
EAM
40
Exane Asset Management
France
$1.2M +$73.4K +7,000 +7%
Bank of America
41
Bank of America
North Carolina
$1.13M -$282K -26,931 -21%
Squarepoint
42
Squarepoint
New York
$1.06M -$441K -42,064 -31%
FI
43
Fosun International
China
$1.03M +$472K +45,012 +86%
Citigroup
44
Citigroup
New York
$1.03M +$665K +63,384 +222%
Swiss National Bank
45
Swiss National Bank
Switzerland
$941K +$62.9K +6,000 +8%
HP
46
Harbourvest Partners
Massachusetts
$889K – – –
KCM
47
Kennedy Capital Management
Missouri
$847K +$792K +75,507 New
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
$821K +$24.6K +2,350 +3%
Rafferty Asset Management
49
Rafferty Asset Management
New York
$815K -$187K -17,854 -20%
ARTA
50
A.R.T. Advisors
New York
$811K +$758K +72,291 New
1
2
3 4 5

CTMX Hedge Fund Activity: Q2 2019 in Review

109 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2019, worth a combined $400M — up 0.07% from $399M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of CTMX and 20 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 43 added.

The largest buyer was Nuveen, opening a new position worth an estimated $7.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $10.3M sold.

  • 109 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2019, down from 113 in Q1 2019.
  • Funds reported $400M of CytomX Therapeutics stock for Q2 2019, up 0.07% quarter-over-quarter.
  • 20 funds opened new CytomX Therapeutics positions in Q2 2019 and 22 closed out, a net change of -2 holders.
  • The largest CytomX Therapeutics buyer in Q2 2019 was Nuveen, an estimated $7.8M added.
  • The largest CytomX Therapeutics seller in Q2 2019 was Great Point Partners, an estimated $10.3M sold.

Based on aggregated 13F filings for Q2 2019.